Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
about
Evaluation of BM cytomorphology after allo-SCT in patients with AML.Hematopoietic stem cell transplantation for MDS.Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematolCurrent status of allogeneic hematopoietic cell transplantation for MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.Standards and impact of hematopathology in myelodysplastic syndromes (MDS).Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?When to transplant MDS, and what to do when transplant fails.Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Myelodysplastic syndromes with bone marrow fibrosis.
P2860
Q30318110-C51D1FC8-CAC5-418D-BF45-6E353568FE98Q33767314-ACC66674-F87F-464D-AF57-71F5A8DBB337Q34543049-CFD1F807-251A-43A3-81B9-DDDC18B4AF7AQ35925067-1181FCF1-894E-45D5-BA68-67AACBFC2465Q36063049-97E19BF0-392C-45C2-92D4-F32EFAB1CF80Q36431041-83BF380A-0EEC-4CBE-A4D4-87E0FD95ABCAQ36811828-5968E59C-4A3F-4216-9957-88C97643CE8AQ37110816-5E4AB19C-E14B-4C86-BADA-C44F47E36C5FQ37521161-CDCA1FA7-54FC-4E8E-853E-D658FB9C1D81Q37840934-B54919AE-3802-4A61-BE2D-9F1869F17109Q37964938-AF793395-AA0A-417B-AFA8-585FCC4A0792Q37968531-435B33DE-5F57-460C-A714-D65C3E16F6D7Q38148983-995E0B72-4945-43DD-9205-EFA3AA9D84F7Q39811365-4E2CADFE-17E6-41F3-BE22-8DEB5BA8D545Q42586754-203CFE04-9999-4C8A-A88E-C0DAE895AD85
P2860
Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@en
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@nl
type
label
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@en
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@nl
prefLabel
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@en
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@nl
P2093
P50
P1476
Marrow fibrosis as a risk fact ...... a with multilineage dysplasia.
@en
P2093
Bart L Scott
Joanne E Greene
Robert C Hackman
P304
P356
10.1016/J.BBMT.2006.10.030
P577
2007-03-01T00:00:00Z